Free tool
FAERS Monitor: Lynparza
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208558 or its brand name (Lynparza, Olaparib). Reports on generic versions are filed under their own applications.
Reports
21,443
Serious
19,511
91% of reports
Hospitalization
3,959
Death reported
6,079
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death4,833
- malignant neoplasm progression2,129
- nausea1,903
- fatigue1,836
- anaemia1,670
- off label use971
- vomiting761
- neuropathy peripheral709
- drug ineffective689
- asthenia650
- diarrhoea638
- decreased appetite565
- disease progression537
- myelodysplastic syndrome493
- haemoglobin decreased456
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2012 | 6 |
| 2013 | 1 |
| 2014 | 6 |
| 2015 | 372 |
| 2016 | 506 |
| 2017 | 649 |
| 2018 | 851 |
| 2019 | 1,426 |
| 2020 | 2,047 |
| 2021 | 2,215 |
| 2022 | 2,367 |
| 2023 | 2,863 |
| 2024 | 3,375 |
| 2025 | 2,747 |
| 2026 | 2,011 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,032,716 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myelodysplastic syndromeSignal | 493 | 34.6 | 31.6 | 15,506 |
| malignant neoplasm progressionSignal | 2,129 | 20.8 | 20.0 | 39,473 |
| anaemiaSignal | 1,670 | 8.7 | 8.3 | 11,304 |
| neuropathy peripheralSignal | 709 | 7.4 | 6.8 | 3,878 |
| deathSignal | 4,833 | 5.5 | 5.4 | 18,581 |
| disease progressionSignal | 537 | 4.5 | 4.1 | 1,443 |
| haemoglobin decreasedSignal | 456 | 4.4 | 4.0 | 1,183 |
| decreased appetiteSignal | 565 | 2.4 | 2.2 | 459 |
| nauseaSignal | 1,903 | 2.4 | 2.3 | 1,547 |
| fatigueSignal | 1,836 | 2.3 | 2.2 | 1,421 |
| asthenia | 650 | 1.7 | 1.6 | 188 |
| vomiting | 761 | 1.6 | 1.5 | 169 |
| off label use | 971 | 1.1 | 1.0 | 7 |
| diarrhoea | 638 | 1.0 | 0.9 | 1 |
| drug ineffective | 689 | 0.5 | 0.5 | 340 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.